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OBJECTIVE
To determine whether an intensive lifestyle intervention (ILI) designed to sustain
weight loss and improve physical fitness in overweight or obese persons with type 2
diabetes was associated with bone loss after 4 years of follow-up.
RESEARCH DESIGN AND METHODS
This randomized controlled trial of intensive weight loss compared an ILI with a
diabetes support and education (DSE) group among 1,309 overweight or obese
subjects. Bone mineral density was assessed at baseline and after 1 year and 4
years of intervention.
RESULTS
ILI was effective in producing significant weight loss (5.3% vs. 1.8% in ILI and DSE,
respectively; P < 0.01) and increased fitness (6.4% vs.20.8%) at year 4. In men, ILI
participants had a greater rate of bone loss during the first year (21.66% vs.
20.09% per year in ILI and DSE, respectively). Differences between groups were
diminished by one-half after 4 years (20.88% vs.20.05% per year in ILI and DSE,
respectively) but remained significant (P < 0.01). The difference in rate of hip bone
loss between groups over 4 years was related to increased weight loss in ILI.
Among women, the rate of bone loss did not differ between ILI and DSE after 4
years.
CONCLUSIONS
A 4-year weight loss intervention was significantly associated with a modest in-
crease in bone loss at the hip in men but not in women.
Type 2 diabetes affects a significant proportion of the population in North America,
with an incidence directly proportional to the development of obesity (1). Weight
loss has been shown to be effective in improving cardiovascular disease risk factors
and slowing progression to type 2 diabetes among high-risk obese adults (2). How-
ever, weight loss has also been associated with diminished bone mineral density
(BMD) (3–5).
The impact of type 2 diabetes on bone has been reviewed (6,7), but only two
publications could be identified that characterized bone loss with weight loss and
exercise in adults with type 2 diabetes (8,9). One study showed a reduction in bone
loss with resistance training in addition to caloric restriction compared with caloric
restriction alone (8). The Look AHEAD (Action in Health for Diabetes) Trial presents a
unique opportunity to examine the longitudinal impact of lifestyle modification on
bone mass in a large cohort of overweight and obese subjects with type 2 diabetes.
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Data from the 1-year follow-up of the
Look AHEAD Trial documented significant
loss of bone at the total hip and femoral
neck, which was proportional to weight
loss (9). The intensive lifestyle modifica-
tion was designed to promote substantial
weight loss during the first year and to
maintain weight in subsequent years.
The impact of this intensive lifestyle mod-
ification, which sought tomaintain the ini-
tial weight losses over time, on long-term
changes in BMD remains unknown but
maybeof significance for the pathogenesis
of fractures. The studies of Armamento-
Villareal and colleagues (3–5) docu-
mented a protective effect of physical
activity on hip bone loss resulting from
loss of weight in an elderly nondiabetic
obese cohort. This seminalwork still leaves
open whether the same effect may be
characteristic of weight loss in overweight
or obese people with type 2 diabetes.
This study examined whether individ-
uals who participated in the intensive
lifestyle intervention (ILI) for 4 years
in the Look AHEAD Trial have a greater
loss of BMD at the hip than participants
in the standard diabetes support and
education (DSE) (control) treatment
arm. The BMD of the hip was chosen
as the primary outcome variable be-
cause it is less susceptible to artifacts
from degenerative changes that occur
frequently in individuals .60 years of
age (10). We also examined whether
this change in hip BMD reflects that of
the lumbar spine, femoral neck, and to-
tal body BMD and whether changes in
BMD at the hip and lumbar spine were
proportional to change in weight and
fitness.
RESEARCH DESIGN AND METHODS
Subject Selection, DXA, Physical
Activity, Fitness, and Dietary Calcium
Intake
Subjects were recruited into the Look
AHEAD Trial as previously described
(9,11). Participation was limited to peo-
ple with type 2 diabetes from 16 clinical
centers in the U.S., those 45–76 years
old, and those with a BMI $25 kg/m2
(or $27 kg/m2 if taking insulin). Sub-
jects were randomized to either ILI,
including a weight loss diet and in-
creased physical activity, or DSE. The
goal of ILI was a sustained 7% loss of
weight during the first year, with weight
maintenance thereafter. A substudy
was conducted at five clinical sites to
measure longitudinal changes in bone
density and body composition by DXA
scanning as previously described (9).
All randomized subjects at these five
sites (1,479 of 5,145 total) were ap-
proached to participate in the DXA sub-
study with the exception of those who
weighed over the weight limit for the
scanner (300 lb). A total of 1,373 sub-
jects consented to and completed base-
line assessments of body composition,
including total body BMD (including
the head), BMD of the lumbar spine
(L1–L4), total hip, and the femoral neck
of the hip, using a Hologic fan beam den-
sitometer. Of these, 1,274 subjects
had a scan 1 year after randomization
(Y1) and 1,158 subjects after 4 years
(Y4); 1,123 of the 1,158 Y4 subjects un-
dergoing DXA scans also had a Y1
scan. A total of 1,309 subjects within
the current database had a DXA scan
at baseline and at least one follow-up
assessment. The common reasons for
missing data were loss to follow-up
and weight .300 lb. A complete ac-
counting of the subjects is detailed in
the Supplementary Data.
At baseline, Y1 and Y4 clinic visits,
weight, height, prescription medication
use, demographic characteristics, smok-
ing history, alcohol use, calcium intake
in the diet (but not supplement use),
and A1C were obtained as described
(9). Fitness, expressed in METs, was
quantified from a submaximal graded
exercise test (12). The MET level pre-
sented is that at 80% of the subject’s
maximal heart rate. Graded exercise
test measures were done at the same
visit as the DXA measures or within 1
week of each other if not on the same
day. Physical activity was quantified
in a subgroup of Look AHEAD partici-
pants in kilocalories per week at base-
line, 1-year, and 4-year follow-up from a
self-reported questionnaire developed
by Paffenbarger et al. (13) for assess-
ment of leisure-time physical activity.
Of 1,309 participants in the data set
for this article, 564 have leisure-time
physical activity data (43%). Calcium in-
take from food was quantified from a
food frequency questionnaire in a sub-
group of 50% of the subjects seen at each
clinic site and accounted for 54% of the
current cohort (14). Data related to bone
fractures, which was considered a final
outcome measure for the larger trial,
were not accessible for this article.
Statistics
Mean and SD were computed for contin-
uous baseline measures, and frequen-
cies and percentages were computed
for categorical baseline measures. Base-
line data were analyzed to assess the
effectiveness of the randomization and
differences by sex. All analyseswere con-
ducted by sex.
BMD outcome measures were ex-
pressed as absolute differences in areal
density (g/cm2), an acceptedmeasure of
bonemass per a two-dimensional space,
which is the actual quantity obtained
from a DXA scan, and as percent change
frombaseline [(Y4BMD –baseline BMD) /
(baseline BMD) 3 100]. Additionally,
mean and SD were calculated by treat-
ment arm on the Y4 change in the BMD
of lumbar spine and total hip and the Y4
change in continuous measures of inter-
est: weight, fitness, physical activity,
and A1C. These means were tested by
treatment arm for differences using
t tests. To examine the relationship be-
tween Y4 and Y1 changes in lumbar
spine and total hip BMD, the Y4 changes
were examined as a function of the Y1
changes. The within-arm mean baseline-
to-Y4 change was tested for equality to
zero using t tests for the outcome mea-
sures. An ANOVA was used to test for
differences in change between the ILI
and DSE arms. The categorical measures
(smoking status, alcohol use in the past
year, menopausal status, proteinuria)
and arm of the study completed the list
of independent variables of interest.
Generalized linear modeling (GLM)
procedures, adjusting for site, were
used to examine the relationship be-
tween Y4 BMD change (response vari-
ables) and predictor variables identified
as correlated with the outcome mea-
sures. As noted, fewer paired Y1 scans
were available than for the Y4 cohort,
and to take this into account, an available
data method as opposed to a complete
case method was used. No imputed data
(e.g., last observation carried forward)
were used.
We examined correlations to identify
potential confounding or colinear vari-
ables. The variables change in weight and
change in fitness were identified as pre-
dictor variables based on a visual exam-
ination of the bivariable scatterplots,
biological plausibility, and significant
change over the 4-year interval. Change
in A1C was added to the list because of
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its clinical significance as a marker of di-
abetes disease control. All models were
adjusted for age, diagnosed diabetes du-
ration, baseline BMI, site, race, baseline
insulin, thiazolidinedione (TZD) use,
menopausal status (for women), pro-
teinuria, smoking status, and baseline
level of the response and predictor
measures. Repeated-measures (mixed)
modeling was used to assess the rela-
tionship between time and change in
BMD and was more fully adjusted for
Y1 changes in weight and BMD. For the
GLM and the repeated-measures model-
ing, the by-arm interaction was evalu-
ated for all significant main effects
among the independent measures.
Rate of change (b) estimates are re-
ported for continuous measures, and
adjusted means are reported for cate-
gorical measures. Significance was de-
termined using a fixed a= 0.05. All
analyses were performed using SAS 9.2
(SAS Institute, Cary, NC) software. The
significance of the total hip BMD results
was also assessed using a calculation of
Cohen’s d for estimating the effect size
(15) for the ILI arm compared with the
DSE arm.
Sensitivity analyses were performed
to examine the impact of age and gluco-
corticoid and TZD use because they have
been shown to be deleterious to bone
(16–21). Additional analyses examined
the impact of age, bariatric surgery,




The baseline characteristics of subjects
in the two study groups are summarized
in Table 1, as are the variables describing
the DXA subsample and the full Look
AHEAD cohort (Supplementary Data).
Randomization was generally successful
in distributing subjects equally for de-
mographic variables in the overall trial;
however, weight differed significantly
across treatment groups (P = 0.049).
There was a very low prevalence of os-
teoporosis (defined as a T-score,22.5)
at any site of measurement at baseline
and no difference in prevalence be-
tween groups.
The demographic variables of the
subsample of the Look AHEAD cohort
participating in the bone substudy dif-
fered from the total Look AHEAD cohort
(Supplementary Data), reflecting the
Latino population at these participating
centers. The DXA cohort was shorter,
weighed less, had a lower BMI, was
more fit, was more likely never to have
smoked, was treated less frequently
with TZDs and steroids, and comprised
fewer blacks and non-Latino whites.
Changes in BMD Comparing ILI and
DSE
Men randomized to ILI had a twofold
greater rate of bone loss at the hip
(20.78% per year) than those random-
ized to DSE (20.36% per year, P, 0.01)
at Y4, with an effect size of 0.42. How-
ever, no intervention effect on lumbar
spine BMD (0.34% vs. 0.33% per year,
P = 0.99) was found. The changes in
male total hip BMD were also reflected
in similar changes at the femoral neck.
Women in both treatment arms had de-
creases in all measures of BMD (0.26–
1.31% per year), and in contrast to men,
there were no significant differences
(P $ 0.24) in mean BMD loss between
treatment groups by Y4 at any site.
Effects of Treatment Arm on Alcohol
Intake, Smoking Status, Dietary
Calcium Intake, Weight, and Fitness
at Y4
Primary explanatory variables believed
to affect change in BMD from baseline
are summarized in Table 2, stratified by
sex and intervention arm. There was a
statistically significant effect of ILI to
reduce body weight and BMI and in-
crease fitness in both groups, but phys-
ical activity was only increased in men.
No statistically significant effect of
treatment arm on alcohol intake in the
past year, smoking status, or dietary cal-
cium intake in either men or women
was found.
Effect of Sex, Weight Loss, and
Glucose Control on Bone Loss to Y4
Adjusted for Weight
Among men, the magnitude of weight
loss was significantly correlated with
bone loss at the hip (b = 0.03, P ,
0.001) but with some gain in spine
BMD (b = 20.02, P = 0.005) (Table 3).
In women, the magnitude of weight loss
was also significantly correlated with
bone loss at the hip (b = 0.05, P ,
0.001) but not at the spine (b =
20.008, P = 0.251). Hip bone loss did
not correlate with change in fitness in ei-
ther sex. Improved glycemic control, as
reflected by lower A1C levels, correlated
with loss of bone in the lumbar spine in
men and hip bone loss in women. A sta-
tistically significant20.4% (4 mmol/mol,
P, 0.01) decrease in HbA1c in the ILI arm
compared with the DSE arm was ob-
served in men only in this DXA cohort,
which can be estimated to account for
0.04% per year spine BMD loss.
For change in total hip BMD in men,
there was no longer a significant differ-
ence by Y4 between the ILI and DSE arms
(rate of BMD loss 20.53%, P = 0.93) af-
ter adjustment for postrandomization
changes in weight. In women, after ad-
justing for these changes, ILI was associ-
ated with less (21.01% per year) Y4 hip
bone loss compared with DSE (21.27%
per year, P = 0.005).
In a sensitivity analysis that ex-
cluded subjects using any steroid,
TZD, or bisphosphonate at baseline,
the results were similar. Only 12.8% of
the sample was using inhaled or topical
steroids not generally believed to be det-
rimental to bone; 5.4% was using oral
steroids known to cause bone loss; and
1.5%was using bisphosphonates, a med-
ication known to increase BMD meas-
ures. The use of steroids was similar in
the ILI and DSE groups. There alsowas no
significant difference (P = 0.355) in TZD
use across arms of the DXA substudy or
by sex. Adjusting for age did not signifi-
cantly change the results. For example,
the rates of bone loss at the hip at Y4 in
women for the ILI and DSE groups were
21.38 and21.31% per year with adjust-
ment for age vs.21.33 and21.27% per
year after removing the age adjustment.
Of the 1,309 participants included in
these analyses (i.e., those who had
baseline and at least one follow-up
DXA scan), 19 reported having bariatric
surgery by the time of the Y4 visit (6 in
ILI, 13 in DSE). Only 2 of these 19 partic-
ipants (1 in each arm) had bariatric sur-
gery by the time of their Y1 visit. There
are no significant differences at Y1 in
weight loss and bone loss of those
with and without bariatric surgery by
Y4. By Y4, those in both the ILI and DSE
arms with the bariatric surgery had sig-
nificantly more weight loss and bone
loss than those without the surgery.
The GLM models representing the data
in Fig. 1 were rerun with the 19 bariatric
surgery participants removed, showing
only slight changes in the estimate val-
ues and no change in significance. There
was no significant difference in hip and
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spine BMD for insulin users versus non-
users stratified by randomization arm
and visit.
Effect of Interventions on the Rate of
Interval Bone Loss Between Years
0 and 1 and 1 and 4
The results of a fully adjusted repeated-
measures GLM are summarized in Fig. 1.
The purpose of this model was to deter-
mine whether the effect of the interven-
tion on the annual rate of bone loss
varied over time. A visual inspection of
Fig. 1 shows marked differences in the
pattern of bone loss and weight with
time in men and women. There is a
striking parallel between the changes
in weight and hip BMD in men and a
significant (P , 0.001) correlation be-
tween percent change in lean mass
and percent change in hip BMD at
both Y1 (r = 0.294) and Y4 (r = 0.339).
There was also a significant (P , 0.001)
correlation between percent change
in total body fat and percent change
in hip BMD at both Y1 (r = 0.341) and
Y4 (r = 0.290). A significant (P# 0.0001)
time 3 arm interaction for hip BMD
was found in men as well as in women.
As a percentage of the initial BMD, these
estimated hip losses for men and
women, respectively, were 21.38%
and 20.88% per year for ILI over the
1- to 4-year follow-up intervals. This
model showed a greater rate of bone
loss at Y1 compared with Y1–Y4 at the
hip for both men and women. There was
no significant effect on the lumbar spine
(P value for time 3 arm interaction =
0.591 and 0.935 in men and women,
respectively).
CONCLUSIONS
After 1-year follow-up, we found the
intensive weight loss intervention of
Look AHEAD to be associated with more
rapid bone loss at the hip but not at the
spine in both men and women (9). In
Table 1—Baseline data for subjects from the Look AHEAD trial used for longitudinal assessment of BMD
DSE ILI
Variable Men Women Men Women P value^
Number 252 403 239 (100) 415
Age (years) 60.0 (6.4) 57.8 (6.4) 60.4 (6.4) 57.0 (6.5) 0.390
Ethnicity (number, %)
Black 17 (7) 56 (14) 9 (4) 55 (13) 0.585
White 182 (72) 196 (49) 169 (71) 212 (51)
Other 53 (21) 151 (37) 61 (26) 148 (36)
Height (cm) 175.4 (6.7) 160.4 (6.7) 174.3 (6.9) 160.2 (6.9) 0.157
Weight (kg) 104.9 (14.4) 93.5 (16.0) 103.0 (15.3) 91.9 (16.7) 0.049
L/S spine BMD (g/cm2) 1.15 (0.17) 1.08 (0.16) 1.12 (0.14) 1.07 (0.17) 0.017
Mean T-score L/S spine 0.49 (1.57) 0.15 (1.40) 0.19 (1.31) 0.06 (1.47) 0.027*
T-score ,22.5 for L/S spine 2 (0.8) 10 (2.5) 2 (0.8) 13 (3.2) 0.567
Total hip BMD (g/cm2) 1.10 (0.14) 1.03 (0.14) 1.08 (0.12) 1.03 (0.14) 0.390
Mean T-score total hip 0.30 (0.96) 0.51 (1.10) 0.18 (0.85) 0.53 (1.09) 0.562
T-score ,22.5 for total hip 1 (0.4) 0 (0) 0 (0) 0 (0) N/A
BMI (kg/m2) 34.1 (4.3) 36.3 (5.5) 33.9 (4.6) 35.7 (5.7) 0.142
Diabetes duration (years) 7.2 (6.2) 6.5 (6.1) 7.3 (6.8) 5.8 (5.5) 0.244
Calcium intake (mg/day)# 850.2 (589.8) 844.3 (530.5) 822.3 (508.7) 838.3 (437.1) 0.732*
Insulin use 34 (13) 66 (16) 46 (19) 61 (15) 0.601*
TZD use 66 (26) 68 (17) 56 (23) 63 (15) 0.355
Steroid use 7 (2.8) 86 (21.4) 9 (3.8) 79 (19.1) 0.564
Bisphosphonate use 0 (0) 7 (1.7) 1 (0.4) 10 (2.4) 0.349
Fitness (METs) 6.0 (1.7) 5.0 (1.4) 5.9 (1.6) 5.0 (1.3) 0.710
Leisure-time physical activity (kcal/week) 1,067.8 (1,608.5) 594.0 (1,549.4) 819.9 (1,108.0) 520.8 (824.2) 0.196
Smoking status
Never 98 (39) 258 (64) 94 (39) 267 (64) 0.898
Past 143 (57) 127 (32) 129 (54) 132 (32)
Present 11 (4) 17 (4) 16 (7) 16 (4)
Alcohol in past year 165 (65) 187 (47) 172 (72) 200 (48) 0.160
Menopausal status
Postmenopausal d 311 (77) d 297 (72) 0.054
Premenopausal d 43 (11) d 50 (12)
Unknown d 49 (12) d 68 (16)
Proteinuria (mg albumin/mg creatinine$0.3 on spot urine) 5 (2) 9 (2) 4 (2) 14 (3) 0.499*
A1C (%) 7.3 (1.2) 7.4 (1.2) 7.2 (1.2) 7.3 (1.2) 0.101*
A1C (mmol/mol) 55 (13) 56 (13) 55 (13) 55 (13)
Data are mean (SD) or n (%) unless otherwise indicated. L/S, lumbar spine. ^P value for randomization arm adjusted for sex and clinic. *Sex effect not
significant at the 0.05 a level. #Diet data were only collected on a subset of the Look AHEAD cohort. Numbers for calcium intake were 708 for total
cohort, 258 for men, and 450 for women.
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men, a pattern of increased hip bone loss
with ILI continued through Y4. An acceler-
ated rate of hip bone loss in women at Y1
decreased with ILI by 4 years of follow-
up but persisted in the DSE group such
that the rate of hip bone loss was equiv-
alent between groups by Y4. ILI was ef-
fective in producing significant weight
loss and increased fitness throughout
4 years of follow-up but did not result
in increased physical activity among
women in the DXA subset.
Hip bone loss in men was only mod-
estly increased with ILI, a difference of
;0.4% per year or 1.6% over 4 years in
BMD. The hip bone loss with ILI in men
may reflect the greater weight loss in
this group and correlated with loss of
both lean mass and fat mass. Men in
the ILI arm experienced an average
weight loss of 9.8% in the first year,
whereas DSE participants had stable
weight. In the subsequent 3 years, there
was a small regain of weight in the ILI
arm (mean weight increase 4.1 kg in
men, 1.5% per year weight regain). Of
note, despite this weight regain, more
rapid bone loss in the ILI group persisted
after Y1, although the rate was reduced
compared with the first year of the trial.
Average weight remained lower in the
ILI arm than in the DSE arm, which may
account for the lower, yet persistent
rate of hip bone loss. Neither increased
fitness nor increased physical activity
appeared to lessen the accelerated
rate of hip bone loss observed in the
ILI group in men. Explanations for
the increased spine BMD observed in
the ILI group must remain purely specu-
lative because no mechanistic studies
were included in the design of the trial.
The change, however, could reflect arti-
fact (22–26) due to spine degenerative
changes, a common observation in older
adults (10).
For women, although the ILI group
continued to maintain lower weight
than the DSE group, there was no
longer a difference in the rate of hip
bone loss across intervention groups af-
ter 4 years of follow-up, suggesting that
more rapid bone loss in the ILI group
occurred during the rapid weight loss
phase. When this phase was over and
weight regain began (+3.6 kg from Y1
to Y4), the rate of bone loss from Y1 to
Y4 decreased in the ILI group but contin-
ued unabated in the DSE group, which
continued to lose weight (21.3 kg). By
the end of 4 years, the amount of bone
loss in the ILI and DSE groups thus
converged.
The rate and magnitude of bone loss
at the hip attributable to ILI, adjusting
for all covariates, are small. The effect
size is modest (13). The hip and lumbar
spine BMD values with ILI observed at 4
years of follow-up in the current study
were comparable to values previously
reported in type 2 diabetic and age-
and sex-matched control subjects who
were not subject to sustained weight
loss (27). Sensitivity analyses suggest
that several potentially confounding
factors did not affect the results, includ-
ing the use of steroids, TZDs, or bisphos-
phonates; age; or the disproportionate
Table 2—Summary results for changes in BMD and explanatory (predictor) variables that may affect change in BMD, stratified
by study arm and sex
Men Women
Variable ILI (n = 208) DSE (n = 218) P value ILI (n = 368) DSE (n = 364) P value
BMD measure
L/S spine BMD change (g/cm2) 0.01 6 0.05 0.02 6 0.06 0.72 20.03 6 0.05 20.03 6 0.06 0.38
% change in L/S spine BMD/year 0.3 6 1.1 0.3 6 1.2 0.99 20.7 6 1.2 20.6 6 1.4 0.24
Total hip BMD change (g/cm2) 20.03 6 0.05 20.02 6 0.04 ,0.01 20.04 6 0.05 20.04 6 0.05 0.44
% change in hip BMD/year 20.8 6 1.0 20.4 6 0.9 ,0.01 21.1 6 1.3 21.0 6 1.3 0.46
Explanatory variable
Weight change (kg) 25.9 6 7.8 21.7 6 7.0 ,0.01 24.7 6 7.4 22.1 6 8.1 ,0.01
% weight change 25.7 6 7.1 21.6 6 6.6 ,0.01 25.0 6 7.9 22.0 6 7.9 ,0.01
BMI change (kg/m2) 21.9 6 2.5 20.6 6 2.3 ,0.01 21.8 6 2.9 20.7 6 3.1 ,0.01
% BMI change 25.5 6 7.0 21.6 6 6.6 ,0.01 24.9 6 7.9 21.8 6 8.0 ,0.01
Change in fitness (METs) 0.3 6 1.5 20.1 6 1.5 ,0.01 0.2 6 1.3 20.2 6 1.3 ,0.01
% change in fitness 7.3 6 26.1 20.23 6 25.0 ,0.01 5.8 6 26.5 21.4 6 24.8 ,0.01
Change in dietary calcium (mg/day) 251.1 6 608 247.4 6 656 0.97 281.8 6 431 2164.7 6 534 0.10
% change in dietary calcium 18.0 6 82.4 16.7 6 92.8 0.91 7.3 6 60.5 23.7 6 64.4 0.09
Change in leisure-time physical activity (kcal/week) 466.2 6 1,612 262.7 6 1,659 0.03 204.5 6 1,105 8.8 6 1,653 0.21
% change in leisure-time physical activity 361 6 1,053 192 6 739 0.26 286 6 921 266 6 978 0.87
Change in A1C (%) 20.4 6 1.0 0.05 6 1.2 ,0.01 20.1 6 1.5 0.0 6 1.6 0.51
Change in A1C (mmol/mol) 24 6 11 0.5 6 13 21 6 17 0 6 18
Change in fat mass (g) 22,601 6 5,467 166 6 4,842 ,0.01 21,900 6 5,588 2416 6 5,959 ,0.01
Alcohol use in past year 153 (73.6) 148 (67.9) 0.20 177 (48.1) 174 (47.9) 0.96
Menopause
Post N/A N/A N/A 260 (70.7) 282 (77.5) 0.08
Pre d d d 45 (12.2) 39 (10.7) d
Unknown d d d 63 (17.1) 43 (11.8) d
Smoking status
Never 81 (38.9) 87 (39.9) 0.33 231 (62.8) 234 (64.5) 0.73
Past 114 (54.8) 124 (56.9) 121 (32.9) 117 (32.2) d
Present 13 (6.3) 7 (3.2) 16 (4.4) 12 (3.3) d
Data are mean (SD) or n (%). All differences are Y4 – baseline. Continuous and categorical measures were tested with t test and x2 test, respectively.
N/A, not applicable.
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number of individuals receiving bariatric
surgery for weight loss in the different
arms of the study.
The impact of voluntary weight loss
on BMD in other studies of nondiabetic
subjects has been variable and reported
mostly in obese women (28–30). In two
of these studies, bone loss was found
with weight loss (28,29), but the other
study focused on premenopausal women
(30). In one study of overweight men,
bone loss was found with weight loss
and was comparable between diet-
induced and exercise-induced weight loss
(31). Other studies of nondiabetic sub-
jects have shown a variable impact of
exercise, a component of the current life-
style modification intervention, on BMD.
Exercise increased BMD in premeno-
pausal compared with postmenopausal
women in one study (32), but other stud-
ies have described both increased (33–
38) and decreased (28) BMD in postmen-
opausal women. Exercise appears to
increase BMD in men (38,39), but the ef-
fect is small and not seen in all studies
(40).
The data from the current study sug-
gest that a comprehensive lifestyle
modification program does not com-
pletely compensate for the bone loss
associated with weight loss. The results
differ from those observed in nondia-
betic elderly obese subjects where
weight loss induced by much more in-
tensive physical activity increased hip
BMD (32–36). This may reflect different
participant selection, a much more in-
tensive physical activity intervention in
the latter study, limitations of using a
physical activity questionnaire for as-
sessment of physical activity in the cur-
rent study, or some aspect of type 2
diabetes rendering such individuals re-
fractory to increasing BMD from lifestyle
intervention.
The current findings suggest that the
improved glycemic control associated
with weight loss was also associated
with greater bone loss. Our observa-
tions agree with epidemiological evi-
dence (27) that individuals with worse
glycemic control (higher A1C levels)
have greater BMD either directly or in-
directly through its association with in-
creased BMI and elevated insulin levels,
which may protect bone. In contrast, af-
ter 1 year of follow-up in Look AHEAD,
improved glycemic control, reflected
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reduced total bone loss at the hip in
men but not in women (9).
Strengths of the current study include
it being the largest clinical trial to date
of lifestyle modification with long-term
follow-up and a randomized prospective
design that successfully produced weight
loss and focused specifically on indi-
viduals with type 2 diabetes. This study
also is the first to show a positive time3
intervention arm effect on hip BMD of ILI
in men and women.
There are a number of potential lim-
itations to the current study, includ-
ing lack of data on calcium/vitamin D
supplement use, the prevalence of
bisphosphonate use in the postmeno-
pausal women, and the possible under-
lying secondary hyperparathyroidism
from deteriorating kidney function.
However, there is no a priori reason
that any of these factors should have
been disproportionally represented in
either arm of the study. No direct mea-
sures of vitamin D were included in the
current study. The change in physical
activity by the questionnaire was mod-
est and limited to a subset of the DXA
group, with limited power due to sample
size. The questionnaire captured leisure-
time physical activity, but this ques-
tionnaire has never been validated for
assessing the risk of bone loss or frac-
ture, does not distinguish between
weight bearing and non-weight–bearing
aerobic activity, and remains a major
weakness of the study.
In conclusion, we have found that in
diabetic patients who lose a substantial
amount of weight over 1 year through
ILI and then maintain their weight for
the subsequent 3 years, there is no over-
all effect on hip bone loss in women
compared with DSE. For men, hip bone
loss is more rapid through ILI compared
with DSE, but the amount of additional
bone loss is modest. These results do
not suggest a clinically important effect
of weight loss on the skeleton; however,
fracture results are needed to be confi-
dent of this conclusion.
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